Infliximab
Treatment for Pyoderma
Typical Dosage: 5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks
Effectiveness
90%
Safety Score
48%
Clinical Trials
1
Participants
500
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks
Time to Effect
2-4 weeks
Treatment Duration
Long-term (induction then maintenance)
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$45,000
Monitoring:$2,000
Side Effect Mgmt:$500
Total Annual:$47,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$39,583.33/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$55,882.35
Cost per Remission
$79,166.67
Infliximab Outcomes
for Pyoderma
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+60%
Common Side Effects
Infusion reactions
+10%
Upper respiratory tract infection
+25%
Headache
+15%
Nausea
+10%
Serious infections (e.g., TB reactivation)
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Infliximab in Pyoderma
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
NCT00791557COMPLETEDNA
2 participants
INTERVENTIONAL
Cleveland, United States
Started: Oct 1, 2008